Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David C. Tscharke is active.

Publication


Featured researches published by David C. Tscharke.


Nature Immunology | 2013

The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin

Laura K. Mackay; Azad Rahimpour; Joel Z. Ma; Nicholas Collins; Angus T. Stock; Ming-Li Hafon; Javier Vega-Ramos; Pilar Lauzurica; Scott N. Mueller; Tijana Stefanovic; David C. Tscharke; William R. Heath; Michael Inouye; Francis R. Carbone; Thomas Gebhardt

Tissue-resident memory T cells (TRM cells) provide superior protection against infection in extralymphoid tissues. Here we found that CD103+CD8+ TRM cells developed in the skin from epithelium-infiltrating precursor cells that lacked expression of the effector-cell marker KLRG1. A combination of entry into the epithelium plus local signaling by interleukin 15 (IL-15) and transforming growth factor-β (TGF-β) was required for the formation of these long-lived memory cells. Notably, differentiation into TRM cells resulted in the progressive acquisition of a unique transcriptional profile that differed from that of circulating memory cells and other types of T cells that permanently reside in skin epithelium. We provide a comprehensive molecular framework for the local differentiation of a distinct peripheral population of memory cells that forms a first-line immunological defense system in barrier tissues.


Nature Biotechnology | 2006

A consensus epitope prediction approach identifies the breadth of murine T CD8+ -cell responses to vaccinia virus

Magdalini Moutaftsi; Bjoern Peters; Valerie Pasquetto; David C. Tscharke; John Sidney; Huynh-Hoa Bui; Howard M. Grey; Alessandro Sette

The value of predictive algorithms for identifying CD8+ T (TCD8+)-cell epitopes has not been adequately tested experimentally. Here we demonstrate that conventional bioinformatic methods predict the vast majority of TCD8+-cell epitopes derived from vaccinia virus WR strain (VACV-WR) in the H-2b mouse model. This approach reveals the breadth of T-cell responses to vaccinia, a widely studied murine viral infection model, and may provide a tool for developing comprehensive antigenic maps of any complex pathogen.


Journal of Experimental Medicine | 2005

Identification of poxvirus CD8 T cell determinants to enable rational design and characterization of smallpox vaccines

David C. Tscharke; Gunasegaran Karupiah; Jie Zhou; Tara N. Palmore; Kari R. Irvine; S. M. Mansour Haeryfar; Shanicka Williams; John Sidney; Alessandro Sette; Jack R. Bennink; Jonathan W. Yewdell

The large size of poxvirus genomes has stymied attempts to identify determinants recognized by CD8+ T cells and greatly impeded development of mouse smallpox vaccination models. Here, we use a vaccinia virus (VACV) expression library containing each of the predicted 258 open reading frames to identify five peptide determinants that account for approximately half of the VACV-specific CD8+ T cell response in C57BL/6 mice. We show that the primary immunodominance hierarchy is greatly affected by the route of VACV infection and the poxvirus strain used. Modified vaccinia virus ankara (MVA), a candidate replacement smallpox vaccine, failed to induce responses to two of the defined determinants. This could not be predicted by genomic comparison of viruses and is not due strictly to limited MVA replication in mice. Several determinants are immunogenic in cowpox and ectromelia (mousepox) virus infections, and immunization with the immunodominant determinant provided significant protection against lethal mousepox. These findings have important implications for understanding poxvirus immunity in animal models and bench-marking immune responses to poxvirus vaccines in humans.


Proceedings of the National Academy of Sciences of the United States of America | 2008

Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes

Erika Assarsson; Jason Greenbaum; Magnus Sundström; Lana Schaffer; Jennifer A. Hammond; Valerie Pasquetto; Carla Oseroff; R. Curtis Hendrickson; Elliot J. Lefkowitz; David C. Tscharke; John Sidney; Howard M. Grey; Steven R. Head; Bjoern Peters; Alessandro Sette

Vaccinia virus is the prototypic orthopoxvirus and was the vaccine used to eradicate smallpox, yet the expression profiles of many of its genes remain unknown. Using a genome tiling array approach, we simultaneously measured the expression levels of all 223 annotated vaccinia virus genes during infection and determined their kinetics. For 95% of these genes, significant transcript levels were detected. Most remarkably, classification of the genes by their expression profiles revealed 35 genes exhibiting immediate-early expression. Although a similar kinetic class has been described for other virus families, to our knowledge, this is the first demonstration of its existence in orthopoxviruses. Despite expression levels higher than for genes in the other three kinetic classes, the functions of more than half of these remain unknown. Additionally, genes within each kinetic class were spatially grouped together in the genome. This genome-wide picture of transcription alters our understanding of how orthopoxviruses regulate gene expression.


Journal of General Virology | 2002

Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes

David C. Tscharke; Patrick C. Reading; Geoffrey L. Smith

Previously, we developed a model for testing the virulence and immunogenicity of vaccinia virus (VV) mutants based on the intradermal injection of BALB/c mouse ear pinnae. The model is characterized by a local infection in the inoculated skin without signs of systemic illness, mimicking dermal vaccination with VV. Here a further characterization of this model is presented, including the responses of mice to infectious virus doses as low as 10 p.f.u., a quantification of the infiltrate at the site of infection and use of different virus and mouse strains. The model was then used to compare the pathogenesis of six mutants of VV strain Western Reserve (WR) lacking genes A36R, A40R, A44L, B12R, B13R or B15R with that of appropriate control viruses. All of these genes except B12R and B15R influence the outcome of dermal infection with WR and for A40R and B13R this is the first role that has been reported after infection of mammals. A comparison of new and published results from intradermal and intranasal models is presented, showing that out of 16 gene deletion or insertion mutants of VV, half have phenotypes distinct from controls in only one of these models. Thus, the intranasal and intradermal models are complementary tools for dissecting the genetic basis of VV virulence.


Journal of Immunology | 2005

Regulatory T Cells Suppress CD8+ T Cell Responses Induced by Direct Priming and Cross-Priming and Moderate Immunodominance Disparities

S. M. Mansour Haeryfar; Richard J. DiPaolo; David C. Tscharke; Jack R. Bennink; Jonathan W. Yewdell

Little is known regarding the participation of CD4+CD25+ regulatory T cells (Treg) in TCD8+ responses. In this study, we show that Treg depletion via treatment with anti-CD25 mAb (PC61) significantly enhances TCD8+ responses to influenza A virus, vaccinia virus, and SV40-transformed cells induced by either direct priming or cross-priming. PC61 did not enhance TCD8+ responses in CD4-deficient mice, providing the initial demonstration that PC61 acts on a subset of TCD4+, and not on other cells that express either CD25 or a fortuitously cross-reactive Ag. We further show that Treg selectively suppress responses to the most immunodominant TCD8+ determinants in the three systems examined. Therefore, Treg influence TCD8 immunodominance hierarchies by moderating disparities in responses to different determinants.


Journal of General Virology | 2002

The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence

Nathan W. Bartlett; Julian A. Symons; David C. Tscharke; Geoffrey L. Smith

The vaccinia virus (VV) N1L gene encodes a protein of 14 kDa that was identified previously in the concentrated supernatant of virus-infected cells. Here we show that the protein is present predominantly (>90%) within cells rather than in the culture supernatant and it exists as a non-glycosylated, non-covalent homodimer. The N1L protein present in the culture supernatant was uncleaved at the N terminus and was released from cells more slowly than the VV A41L gene product, a secreted glycoprotein that has a conventional signal peptide. Bioinformatic analyses predict that the N1L protein is largely alpha-helical and show that it is conserved in many VV strains, in other orthopoxviruses and in members of other chordopoxvirus genera. However, database searches found no non-poxvirus proteins with significant amino acid similarity to N1L. A deletion mutant lacking the N1L gene replicated normally in cell culture, but was attenuated in intranasal and intradermal murine models compared to wild-type and revertant controls. The conservation of the N1L protein and the attenuated phenotype of the deletion mutant indicate an important role in the virus life-cycle.


Journal of Virology | 2006

Poxvirus CD8+ T-Cell Determinants and Cross-Reactivity in BALB/c Mice

David C. Tscharke; Wai-Ping Woo; Isaac G. Sakala; John Sidney; Alessandro Sette; Denis J. Moss; Jack R. Bennink; Gunasegaran Karupiah; Jonathan W. Yewdell

ABSTRACT Mouse models of orthopoxvirus disease provide great promise for probing basic questions regarding host responses to this group of pathogens, which includes the causative agents of monkeypox and smallpox. However, some essential tools for their study that are taken for granted with other mouse models are not available for these viruses. Here we map and characterize the initial CD8+ T-cell determinants for poxviruses in H-2d-haplotype mice. CD8+ T cells recognizing these three determinants make up around 40% of the total responses to vaccinia virus during and after resolution of infection. We then use these determinants to test if predicted conservation across orthopoxvirus species matches experimental observation and find an unexpectedly cross-reactive variant peptide encoded by ectromelia (mousepox) virus.


Journal of General Virology | 2002

A study of the vaccinia virus interferon-γ receptor and its contribution to virus virulence

Julian A. Symons; David C. Tscharke; Nicola Price; Geoffrey L. Smith

Vaccinia virus (VV) strain Western Reserve gene B8R encodes a 43 kDa glycoprotein that is secreted from infected cells early in infection as a homodimer. This protein has amino acid similarity with the extracellular domain of cellular IFN-c receptor (IFN-cR) and binds and inhibits IFN-c from a wide range of species. Here we demonstrate that the B8R protein also inhibits equine IFN-c. The 5« end of the B8R mRNA has been mapped by primer extension analysis and the contribution of IFN-cRs to VV virulence was studied by the construction of a deletion mutant lacking the B8R gene (vDB8R) and a revertant virus (vB8R-R) in which the B8R gene was re-inserted into the deletion mutant. A recombinant virus that expressed a soluble form of the mouse IFN-cR was also constructed and studied. The virulence of these viruses was tested in rodent models of infection. In mice, the loss of the VV IFN-cR did not affect virulence compared with WT and revertant viruses, consistent with the low affinity of the VV IFN-cR for mouse IFN-c. However, expression of the mouse soluble IFN-cR increased virus virulence slightly. In rabbit skin, loss of the VV IFN-cR produced lesions with histological differences compared with WT and revertant viruses. Lastly, the affinity constants of the VV IFN-cR for human and mouse IFN-c were determined by surface plasmon resonance.


Journal of General Virology | 1999

A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae

David C. Tscharke; Geoffrey L. Smith

Vaccinia virus (VV) proteins that interfere with the host response to infection are of interest because they provide insight into virus-host relationships and may affect the safety and immunogenicity of recombinant VV (rVV) vaccines. Such vaccines need assessment in animal models and with this aim a model of VV infection based on intradermal injection of BALB/c ear pinnae was developed and characterized. In this model, the outcome of infection is affected by the dose of virus inoculated but virus spread is minimal and the mice suffer no signs of systemic illness. Cellular and humoral immune responses to these infections were measured readily and were independent of virus dose over a 100-fold range. Thus the model seems suitable for the analysis of the safety and immunogenicity of VV mutants lacking specific immunomodulatory proteins or bearing foreign antigens.

Collaboration


Dive into the David C. Tscharke's collaboration.

Top Co-Authors

Avatar

Jonathan W. Yewdell

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Alessandro Sette

La Jolla Institute for Allergy and Immunology

View shared research outputs
Top Co-Authors

Avatar

John Sidney

La Jolla Institute for Allergy and Immunology

View shared research outputs
Top Co-Authors

Avatar

Inge E. A. Flesch

Australian National University

View shared research outputs
Top Co-Authors

Avatar

Tiffany A. Russell

Australian National University

View shared research outputs
Top Co-Authors

Avatar

Bjoern Peters

La Jolla Institute for Allergy and Immunology

View shared research outputs
Top Co-Authors

Avatar

Jack R. Bennink

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Yik Chun Wong

Australian National University

View shared research outputs
Top Co-Authors

Avatar

Howard M. Grey

La Jolla Institute for Allergy and Immunology

View shared research outputs
Researchain Logo
Decentralizing Knowledge